New Trade for May 12th, 2023

Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past.This golden age is also presenting tremendous opportunities for investors. 

Biotech stocks offer the potential for huge long-term returns.  The best biotech stocks to buy right now boast strong pipelines, and some already have winning drugs on the market.  Our pick for the day ticks all of these boxes.  Click here to learn about this biotech beauty before the next leg higher…

Dylan Jovine

Tiny Biotech Wins $75 Billion Patent

Cambridge firm proves its possible to “Find & Replace” cancer cells. The Wall Street Journal reports this small biotech is “Transforming Medicine.” No wonder Goldman Sachs & Morgan Stanley have been quietly buying shares. [Get the name of this little-known stock here >>>.]

---

Novocure Ltd. (NVCR) 

Novocure makes a novel therapy for treating cancer called Tumor Treating Fields (or TTFields). The therapy uses electrical fields to disrupt cancer cell division. TTFields has already been approved for treating glioblastoma (a type of brain cancer) and mesothelioma (a cancer caused by exposure to asbestos). The company is evaluating the therapy in clinical studies targeting non-small cell lung cancer, ovarian cancer, brain metastases, and pancreatic cancer. Combined, these additional indications represent a potential market that’s 14 times greater than Novocure’s current market opportunity making it a high growth stock to watch.

In the last 5 years, global oncology company NovoCure saw its revenue grow at 22% per year. That’s well above most pre-profit companies. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 24% per year, compound, during the period. So it seems likely that buyers have paid attention to the strong revenue growth.